Juno Therapeutics Inc. is stressing the structural differences between the chimeric antigen receptor T-cell therapies in its pipeline after two fatalities caused it to put the brakes on a study of JCAR015 in adult acute lymphoblastic leukemia.
Juno announced the voluntary hold on the Phase II ROCKET clinical trial in relapsed and refractory ALL on Nov. 23, noting that two patients died from cerebral edema
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?